Functionalizations available for this glycan
-
Oligosaccharide building blocks (13 products)
-
DBCO (1 product)
-
Thiol (1 product)
-
Maleimide (1 product)
-
Azide (2 products)
-
Amine (5 products)
-
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with free terminal amine (Linker-NH2 A) -
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with free terminal amine (Linker-NH2 B) -
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with free terminal amine (Linker-NH2 C) -
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with free terminal amine (Linker-NH2 D) -
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with free terminal amine (Linker-NH2 E)
-
-
Alkyne (3 products)
-
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with terminal alkyne (Linker-CΞCH A) -
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with terminal alkyne (Linker-CΞCH B) -
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) with terminal alkyne (Linker-CΞCH C)
-
-
-
Functionalized oligosaccharides (6 products)
-
Biotin (3 products)
-
Desthiobiotin (1 product)
-
Fluorescein (1 product)
-
Stearic chain (1 product)
-
-
Oligosaccharides grafted on proteins (5 products)
-
HSA (2 products)
-
KLH (1 product)
-
OVA (1 product)
-
CRM197 (1 product)
-
-
Glycan-based affinity column (2 products)
-
Dual-functionalized oligosaccharides (3 products)
-
Biotin and Fluorescein (1 product)
-
Biotin and Stearic chain (1 product)
-
Customizable dual functionalization (1 product)
-
- mail Customized functionalizations on request
Blood group H antigen triose type 5 / 2’-Fucosyllactose (2'-FL) (>99% HPLC)
Product code: GLY031-3-99%
Glycan structure: Fucα1-2Galβ1-4Glc
Synonyms: Blood group H trisaccharide type V;
You can also create a quote from your cart
Chemical formula: C18 H32 O15
Molecular weight: 488.43
CAS N°: 41263-94-9
Synonyms:Blood group H trisaccharide type V;
Laboratory reagent for research and development only. Not for human or animal use.
